Fintel on MSN1d
JMP Securities Initiates Coverage of KalVista Pharmaceuticals (KALV) with Market Outperform Recommendation
Fintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Market Outperform recommendation. Analyst Price Forecast Suggests 219.11% ...
Why Pharvaris (PHVS) Is Advancing Today
Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...
JMP reiterates Kalvista stock with $19 target, sees market growth
JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...
KalVista initiated with an Outperform at JMP Securities
JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...
Optimistic Buy Rating for KalVista Pharmaceuticals Amid Promising Launch of Sebetralstat
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...